This phenomenon shows that the addition of an SGLT2i to insulin did provide insulin-independent glucose lowering after 6 months, but the effects weaken, which seems to be a contradiction because an SGLT2i as an add-on to metformin treatment gradually reduced %HbA1c from 24 to 104 weeks in T2DM patients [51, 52]. This evidence concerns the gene INS and type 2 diabetes mellitus.